LIFE - Earnings call transcript Q1 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon ladies and gentlemen and welcome to the aTyr Pharma First Quarter 2021 Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time.

As a reminder, this conference is being recorded for replay purposes. It is now my pleasure to hand the conference call over to Ashlee Dunston, aTyr's Director of Investor Relations and Corporate Communications. Ms. begin. may you Dunston,

Ashlee Dunston

and to everyone. XXXX discuss update. and operator, joining operating you us corporate today aTyr's good you, Thank afternoon for results Thank first quarter

and by Leslie and Vice President Shukla, We our Nangle, Dr. Research. joined Jill Broadfoot, today our are President CEO; of Ms. CFO; Sanjay

ATYRXXXX pre-clinical an our and neuropilin-X, Sanjay research for with provide it corporate an program subsidiary, positioning on on our strategy, including ATYRXXXX; including the our call, open update for bi-specific antibody our questions. the handing any will to Pangu On our program review will discovery Leslie the in financial BioPharma. for programs and call back our before current Jill will provide to Sanjay results our clinical up program and financial update

the begin, the this These Harbor disclaims I statements by statements the except this of or turn reflect as I required Except conference statements see forward-looking update differ future to information, forward-looking over to these filings these SEC press historical placed quarterly date most now by Litigation which that our be remind uncertainties call are in forward-looking the underlying to cause change. only statements, recent to circumstances and on included can to should in on facts Act like risks disclaimer the in law, and will Form made on of call Sanjay. statements of would reports questions Pharma Safe everyone and aTyr obligation are for provision speak as under and Before of that to issued XX-Q. Form as well Private statements results facts, Securities management any Reform responses forward-looking from and the we report the factors XX-K circumstances. events, company's statement in Undue they forward-looking forward-looking risk on as not release statements. made, actual those annual reliance the afternoon may such Please as materially involve company's the XXXX. statements

Sanjay Shukla

afternoon, joining for Thank shaping conference for you company. Good be impactful year call. for you, first Ashlee. XXXX everyone, our thank results XXXX an is the up quarter and to us

key data the quarter, third the pre-clinical, the XXXX, we look or clinical, made gained effects important XXXX study. this we and pre-clinical with trial During our and interstitial or ATYRXXXX Phase remain with patients With are advancing quarter year. severe progress lung or in COVID-XX programs. proof-of-concept ATYRXXXX, enrolment complications, meaningful clinical we therapeutic We development completed Phase this tracking for on forward we of insights generated mechanistic our Having first candidate from in focused our our in additional respiratory or ILD in Furthermore, from discovery research [Indiscernible] anti-neuropilin-X lead NRPX XXXX. indication, expected X to anti-inflammatory trial readout Xb/Xa sarcoidosis, regarding antibody pulmonary disease our towards obtained our clinical from in in cancer. at

Virtual of pulmonary XX in Details new the of have organization annual for to collaboration With funded we're [ph] our Pangu March. Pangu, since advisor a to with of milestone to on for models FSR, first development. and grant of last the posted year Technology BioPharma, and and promoted the data from develop XXXX for cancer our research for to scientific lung Innovation highly of in of breast cancer. for by member Research. and XXXX encouraged team, President or advocate, support will the for Wilson, managing Kong former a negative University as Dr. on Vice progression and agreement Nangle In achieved President Leslie Cancer patient the an platform and executive clinical with to operations. of a our into the Town We need discovery company. the in triple we've the leading at accomplished Science of Research discuss American Hong Foundation biology Sarcoidosis non-small high the of this participating and project a FSR, Steroids we contract a development for Sarcoidosis cell the a by entered Dr. Hong Hall our We're two-year of with and the a Nangle Hong sarcoidosis government serve of manufacturer forward leadership stage therapeutic of subsidiary, Kong pre-clinical and [Indiscernible], a finally, the part burden NRPX. begin what targeting Technology upon of year together highlights Research thus Board manufacturing year. a we pre-clinical additional options. Kong spoke summarize been to [Indiscernible] for -- meeting programs and Kong few I Hong the building we As development antibodies this novel Directors Andrea in to platform from Co-Founder forward bi-specific the pipeline throughput look far. Commission Association And member

and selectively cells lung known in on and therefore, potential enriched and immune upregulated the resolve normalize lung serving to immune inflammatory binds inflammation XXXX alleviate to to been pre-clinically with the for states. chemokine and that XXXX has inflamed inflammatory treatment is play NRPX XXXX aberrant to progressive begin first-in-class disease. morbidity thereby program inflammation severe a disease and prevent inflammatory shown clinical for Let's role lung to reduce in downregulate our is inflammation and downregulates and XXXX NRPX potential fibrosis. is system, immunomodulator cytokine mortality. as stabilizing XXXX. tissue. We're has developing immune key responses signaling a function and potential in fibrosis,

a group rare Our of of fibrosis is that disorders lung. on ILD, program progressive focused lead cause immune-mediated the

inflammatory with granulomas the Our by characterized of immunosuppressive immune clumps therapies, then of efficacy form initial formation not function. sarcoidosis, treated, it can most of lungs. and options of limited which often treating ILD cells ILD, the have lung scarring diminished corticosteroids indication the irreversible the and pulmonary or other is in If Current limited and toxicity. a are lead or treatment which serious long-term to inflammation include

our respond many to do progressive standard some need the spent profile. treatment of deepening for the recently of with these to for with side we've understanding need patients community. made remains a a effort care. better We conservative the for Additionally, There better novel effect not including current time and of disease sarcoidosis, efficacy option needs steroids treatment patients with for work this with options a patients and

promoting have support these a for to to international and an and a dedicated to has the years non-profit Co-Founded Andrea find finding of part disease. this cure Directors. and She FSR, accelerate we as as cure care now leading for As a appointed improving President and member served to efforts, dedicated previously awareness its the generating Wilson, research advisor patients of company. Board past the patient XX to organization of advocate, these sarcoidosis Andrea the

and firsthand a at help the shedding a malignancies. was point such and limited on side cytotoxic as to severe panel patient the and Town [Indiscernible]. on their evidence malaise, board used decreased invited are sarcoidosis, condition review Sarcoidosis the to we volunteers, sarcoidosis. receive some and of of light of in as here highlighting a these effects April chronic XXXX on of need infection, have this clinical generally treat immunosuppressive, patients such of in to this complications, each a deserve improved side assessed Virtual in treatment. pulmonary XXXX use steroids to Currently sarcoidosis In ongoing during significant favorable majority effects steroids clinical no with these Phase will associated community studies we contributions join her two better safety options XXXX steroids patient a was two own Phase This discuss in course So, with by steroids recent Phase do hyperglycemia, data favorable option effort safe Hall treatments support on X toxic the to Really our as can pulmonary profile. were even could potential a more and strategies of available to participate shown attention and from This a bone Officially, their Awareness and profile, disease, transformative part manage. includes better. from leading are living agents study Month bind other X on with effects cataracts, and clinical highly toxicity, in be of sarcoidosis sarcoidosis and will advocacy a alternative serious Corticosteroids patients which monitoring FSR liver mechanism, today, sarcoidosis. and safety safety with with to for in patients debilitating in knowledge patient drug and the supporting perspective, strategies relationship the proof future. be presents the adverse that to related are believe Xb/Xa to treatment steroids events. COVID-XX XXXX the healthy and effective. provided in has for look a included standing patients advancing for better. the In study each We was well-tolerated study I related the and outcomes. with with The Based of density, studies, to respiratory associated data long sarcoidosis real-world forward honored and sarcoidosis panel, experience their patients and pulmonologist. XXXX obesity, brought program firsthand

every As dose the for is multiple sarcoidosis trial objective a of three The and reminder, testing doses placebo-controlled our pulmonary placebo, pulmonary and clinical study consists trial XXXX three, ongoing ascending dosed of one, tolerability of five this of in ascending month per of sarcoidosis months. evaluate to intravenously is milligrams of Xb/Xa Phase double-blind in This doses trial for kilogram XXXX. XX multiple six safety randomized primary patients. cohorts

assessment imaging, design, serum function of such function treatment effects this to steroid-sparing pulmonary assessments compared the groups tests, relevant as of exploratory and XXXX XXXX Based the burden addition on the an lung trial by objectives integral our in Secondary study to assessed other biomarker. include in of of potential steroid element placebo. lung

available here look Nangle, the quarter steroids. I'd to like the not report in year. Leslie side of need As expect of to toxicity due Research. today, a alternative Dr. third for of the and the which in turn this over call existing options results we'll is the discuss We study to including we there crucial to to VP treatments, to treatment effects forward

recently of Leslie having research company's to her the in from dedicated updates recent NRPX pleased our and since company her aTyr served our roles in XXXX. have pipeline to Co-Founder research antibody joining the to We're with pathways review mentioned, today very Leslie executive with aTyr's studied leadership the program. scientific As at research tRNA under and synthetase operation. to and proportion has career Having I scientific to the team manage regulate. we promoted they us starting

Leslie Nangle

in initiated the biology you, NRPX we've the Thank in bear over gratifying bit I'll some us time I are been am particularly both here been about target begin exciting as my is it's Sanjay. be responsibilities in-house the years. really piecing scientific extremely and variety is upregulated field to and our--. of It antibodies thrilled some background at see starting our glioblastoma, to and a therapeutic we and NRPX. including to our particularly the and see years of past on compelling solid operation, that NRPX NRPX, renal, I'm with fruit, About to our today in better research of collaborations oncology encouraging and aggressive mechanism at inflammation. program. we've together which of pleased tenure expand regards aTyr these understand to is continue a such discuss areas, with breast, with experts scope two a to in my enriched to generating the lung, work advance tumors number the tumors. collaborations that targeting related helping highly ago, disease few we from of research underlying of help to a results therapeutic very particularly when

among the recurrence, suppressors expression is tumor block drug include have Antibodies has generated key in earlier cancer addition, on potential immune may pathways cancers, in targeted tumor-associated antibody panel worsen implicated The overall monoclonal is certain as distinct can High progression microenvironment highly and increasingly roles has tumor aggressive validated. NRPX CCL-XX. including signaling which in aggressive target foreign, aspects is that including the NRPX of this XXXX those with becoming current such selectively and to domains VEGF fully cancers selectively pre-clinical NRPX and humanized is therapeutic certain we year, therapies, oncology activity. outcomes selected engineering interacting by in NRPX investigational optimized in our expressed cases NRPX some VEGF, as patient importance In reported survival. between and regulating of others. macrophages where and aTyr candidate cells to chemokine progression, its specifically human-derived been IND and to and internally cancers may functionally in linked some several developed signaling NRPX these agents, resistance NRPX data enabling animal, myeloid-derived compelling Based we such antibody in to to implicated. a both chemotherapy advance team, and on or or new different this of VEGF. as interaction drug models, and

the transition, have of this NRPX with blocking migratory we and that month, made importance chemotherapeutic metastasis. Cancer with strengthen to and pre-clinical EMT of of in VEGF [Indiscernible], therapeutic progress last cells Research between which mediated to EMT American seminal year's two work growth, by generated Just NRPX organoids and of was Specific inhibiting associated derived as agent bevacizumab, have link signaling for high anti-cancer epithelial a involved related tumor EMT which tumors progression, our a cancer implicated at Annual these types by TNBC, presented triple-negative the progression, sensitized research to demonstrate widely cells regulate data models, VEGF build tumor growth down scientific used and the signaling of two mediates be acquisition suggests particular, we mesenchymal in as stemless, and Furthermore, we genes the solid the confer the of through XXXX cancer, NRPX mechanism University VEGF and towards advisors, tumors types its microenvironment, as of assays anti-tumor presented of of treatment process times ability signaling tumors. upon or Dr. regulator we XX central The walking XXXX expression, mesenchymal tumor In posters cascade, the the the The therapy of two cells. cancer. we being presented, Association data and regulating or to was tumor as in therapeutics, immune tumor patient stages. potential lung This These his researcher regulating these to cisplatin, the cell In posters of understanding insights EMT processes. in the posters well properties the which that lab the in in breast expression our work strengthen was approach Meetings, increasing like understanding a impact may invasive XXXX SI our leading tumor or inhibit and system. targeted Massachusetts shown metastatic School. of significant well down one inhibiting NRPX tumor conducted represent in at non-small collaboration effects as xenograft into epithelial growth. tumor the including TNBC, presented cell Medical is in with potential one effects. can various underlying NRPX blocking stem the tumor that the each part or is Mercurio, tumor Arthur EMT, of great features in

and render cancer tumor cells therapies the stem them advancement with be cell major to be promote more Those addition a conventional have ability efficacy antibody to patients as generated a in solid agent the TNBC, The tumor aggressive data away challenge In potential aggressive of has both lung cancer. with models, we there'll of combination resistance. and also because from in metastasis cancer, cell demonstrating to phenotype with chemotherapy. and susceptible is including this for a tumor other non-small single data significant recurrence differentiation to

assays, sensitizing and invest EMT stem to through continue ability inhibiting We its effect VEGF its block particular the the in cancers its signaling NRPX to including chemotherapy, XXXX and on aggressive properties. cell to cancer on effect

upcoming xenograft [Indiscernible] We our at mechanism, expect later on patient month. including derived the models stem from this this more present findings cells to scheduled research cancer of evolving on for in

further both mechanism compelling our plan its pre-clinical very immune XXXX for understanding clinical the are cells forward that trials thus example We critical to as generated action with treating pleased well of cells in made to the a to themselves, we've far in We as microenvironment progress XXXX support tumor tumor data on leverage in data to for enabling IND really look aggressive and build tumors. to XXXX strategy inform solid activities package the future. continuing for and

clinical XXXX, we for the this with we Last we agreement progressing to IND are manufacturer month, with program As enabling development. our announced into activities we've to for of that Lonza XXXX. continue entered stage an committed

partner in to a to with of first development the of be in with very anti-NRPX biopharma important the uptick now proven especially moving in to chain program due manufacturing and help for COVID-XX stage best demand us antibody these the working supply and the capabilities our this pleased that this extensive manufacturing increased for part of was Having feel a in will at production activity We rise securing antibody. investing for manufacturing, the which is in We are capabilities to XXXX commitment pandemic. due a forward. serve result

the NRPX. Commission, year Technology be Pangu Innovation certain relevant grant Last the a antibodies Science development awarded the high our with was Hong for from antibodies targeting the distinct present Kong highly therapeutically in our create approach to and addition Pangu inflammatory that bi-specific platform In role based or of is is various in & together antibody Hong on a Kong antibodies to agonists on of engineering HKUST approach disease $XXX,XXX a of co-receptors. working to selectively Kong in throughput specific processes believe in-house which approximately platforms with bi-specific the may target Technology Hong domains We unique states. of and government subsidiary interaction that system, NRPX, regulating University developing bi-specific

VEGFRX are forth this We has antibodies part to differentiated numerous yielded which and unique explore. far considered this implementation so have Pangu are and week to and novel of targets project co-receptor PLXNAX high approaches set have the single-cell of HKUST An of antibody project. for targeting antibody milestone in development and as increasingly pipeline being approach, present the a pleased opportunity discovery Bi-specific that same approach a candidate integral NRPX announced a and to and affinity the currently assets. screen us year first a achieved relevant novel functional was

are the second year forward thus turn far project. We Officer will this review the of this that, to to outcome progress Jill over excited and to Chief Broadfoot financial results. of it about look Financial very With I our our

Jill Broadfoot

million increased you, $X was and ended XXXX, March ended increased XXst, Thank months agreement XXXX, HKUST license company’s research for revenues million and collaboration manufacturing and primarily under months XXXX Kyorin. months consistent three were March the and government. the at ended related program respectively. the months XXst, expenses the and Leslie. revenues to development the respectively. Pangu, XXXX, The increase administrative three and million periods primarily XXXX, for between and XXst, costs million between development General and research were related were million license $X.X XXXX respectively. to expenses XXXX $X.X XXXX, of and XXXX March $X.X due to ended three XXst, to related expenses Hong Revenues $X.X Kong three March and for expenses agreement and Research $X.X and Total for the with consisted

its LLC. $X.X During company Capital through LLC at-the-market offering with $XX.X purchase common H.C. quarter Fund, program & million agreement million raised Co., its stock of proceeds of Wainwright the first gross Aspire and with XXXX, through the

March million had in As cash and $XX.X equivalents, cash, investments. XXXX, of XXst, we

and XXXX in trials. for our costs development as clinical and includes increase progress. additional prepare expects of both XXXX to XXXX We This and XXXX to future research XXXX to for manufacturing expenses continue

up Now, it I'd call turn before to over back like Sanjay to to Q&A. the we open

Sanjay Shukla

Thanks Jill.

readout invested in accomplishments key a our solid approach programs. our this a and study we a reflect invested -- for in proof-of-concept and pulmonary its for for mechanism the -- year potential believe presents in Xb/Xa for of of implementing pre-clinical portfolio heavily thoughtful foundation a evolving Our have thoughtful represents work, Phase for to-date clinical robust understanding regenerate the our rationale sarcoidosis hard inform translational XXXX, [Indiscernible] and XXXX inflection data of work and we The of dedication, point that our and really strong pre-clinical action in cancer. which clinical to strategy the same for incredibly XXXX,

capital We ongoing we future. your the and sarcoidosis At take cancer, year. pulmonary the X the to Leslie, through your XXXX this a in have appreciate value us support questions. We updates continued the our for to generate in and progress take you as happy trial providing sufficient Phase readout, and launch and I supports look time, and company which Jill, interest be would to throughout activity

Operator

the Hartaj line [Operator of Instructions] question Your first from Singh comes Oppenheimer. from

Your line is open.

Unidentified Analyst

Hi, everyone. for Jackie Thank our taking Good for in questions. afternoon. Thanks you. Hartaj. It's

the slowly I patients. just I recruited, XX got trial study First, when year trial today's last readout, enrolled the study announced show upcoming remember you patients, XX that show think

And So, you number, additional was then third, Thanks. last not which is XX even an patient is announce maybe are? of patients? fit going are last placebo dropped or obviously And the visit? first, that kind person group, wondered, to reenrolled just which really your cohort some you I just treatment additional wondering patient into that second, and patient that then

Sanjay Shukla

Thanks Sure. Jackie.

ethically can several be is as at passed we a time patients difficult are additional eligible we would through that's have enrollment. that in away At One target So, to patient previously screening. XX, that met you I queue. announced had being final think that turn time, the count imagine, patient -- and

enrollment. that occurred time target we were met we that announcing right So that at when

the enrollment is So, final XX.

three or second cohort. in Your cohort, have is milligram really which our into assigned they our five question backwards around are milligram they been not one cohort,

do patients patient I screening and important had as is, a backfill, that, at XX it's through said, that it's same moved most as want right the a patient allow to not the to really here join. point our the So, simply therefore, and thing time we

but clinical And big that's a a full follow-up and what anything QX enrolment, XX something With things, is think readout. on to last visits more last very target readout on visit, to we're thing I I track around that’s we'll over ethics. in we're issue, regard not really operations those tactical, the not patient consider, think really that main the really third So, patients to basically finish and much on we're focused have any here is up to quarter. have

Unidentified Analyst

about you data Got readout, talk types great. we then that, you or upcoming both And with be And thinking what long-term? steroid those night second, effects for Foundation expecting help a of by could that to different be -- your if more [Indiscernible] would and achieve if on it. time third non-steroidal Thank then frame great release talk that. And -- bit quarter of you will drugs, Sarcoidosis event steroids. last side the side those should us effects, reduction, could that a cohorts, there, short-term

Sanjay Shukla

call, -- do bit Yes, insomnia what effects. a patient's in talked patient irritability, steroids great lot can of heard weight and and from you on toxic a gain that highlighted questions some the effects, mood other a of quite about some about really one particular the about

were originally steroids, actually hitting things many infection heavy a a immunosuppressant, move really those are for as actually agents, chemotherapy. that moved risk, approved know those degree scarier even patients even agents get of toxic malignancy you the concern the many complications, also once that to you higher to of So, is things those have to on see In these quite of we patients. in we where that's more

more a had talking really these toxic of of about that you're patients toxic heavy, immunosuppressants burden to. subtle those to advance some So,

the which could treat think, rather that transformative amount there's it's something of sarcoidosis. and and I and mentioned, interest we how So, it's tremendous to a be I growing changing is in therapy, accelerating paradigm

of burden. to experts ways at going we'd on -- these we a the cumulative see it activity said and of [Indiscernible]. see they that the at this will really better and way to much upcoming focus from six looking important percentage we're around have what activity is burden be reduction, can standpoint over The is One probably with how the way key we'd most highlighting things absolute will the we the burn good But the around steroid feel about an and in be to regards things a like reduction, to here to months expect months, looking XXXX. like

So, a set table to things have we're on. that potentially around these event the are focused expectation. We'll here look all the another to actually really

understand current I that from in experts, from what increased X were for think of a So, reduction confidence of And into if they are steroid we that in observe we this tremendous signal able looking that amount trial. the Phase as move trial. can really I clinical our

Unidentified Analyst

advantages about therapy put it. then is, bi-specific this versus, Got talk University format. And bi-specific Kong, That's kind some Hong you very I rationale the from that guess, candidate earlier helpful. avail a press week combination -- last in of European release can question specific more I you of saw coming tour involving format, what

Sanjay Shukla

working Leslie which as and informed looking your as ask that current in-house, neuropilin-X a just strategy other with of our is us episodes biology quarterback in can we course, even understand other receptors toxins, is, receptors, such we interesting biology, comment really specific our to as it receptor, much well. and integrins, other tuning pointed like neuropilin-X. on targeting VEGF also [Indiscernible] that at colon I'll out. interactions that the chime really But Yes, to is of Leslie

about want really those discovery understanding opportunities it you Hong candidate the and in by mining how mechanism offers pipeline bi-specific And to we government, Pangu bring new the basically more is from Leslie, biology. doing capital of us create on the do side and opportunity the a and new I potentially some receptor collaboration is and even really other leverage learn So, exciting. the approach that of do engagement some is why with neuropilin-X? another just types create this -- Kong of to add of non-dilutive about that anything think

Leslie Nangle

setting technologies Sure, Sanjay. the in as with important as antibody cutting grant bring scheme co-receptors, bi-specific -- absolutely novel receptor, you're create into us mean, sort is those agonists. about I Sanjay and provided But some to non-dilutive grand ways tune actually funding one NRPX this of things some that advanced think edge other realm, a this we under of it of is about opportunity to there really some platform. types and it these forward thinking our I right have, coming that up an on aspect expand the engineering reactions are that with to and together of those well actually if is a really is

monoclonal In of antibodies, time the with we're to of actually natural of most this receptors ligand derive signaling. that NRPX. mono-antibody case, the or NRPX to itself we the together, our bring So, and some co-receptor the blocking can going be

so for want in response to disease example, actually you [Indiscernible] a net that in and And certain capacity. that drives states, may

So, from of coin us well. at as the it side come lets the other it

Sanjay Shukla

one $XX I'll add market, the we've market just when other seen in already thing. approach but just think -- bi-specific billion -- add on at that eventually few A close quarter bi-specifics. about one I'll a to bi-specifics you the

into a a this government, approach. smart with fact Hong way really approach -- us technology future. it's these grants And Kong I think the commercial do bi-specific a to into be is large that in for we opportunity accessing So, us platform the to really, tap the what look could [ph] for can with

Unidentified Analyst

and color the all all you. questions. for Thanks appreciate the Great. really Thank

Operator

from the comes H.C. Branchetti from Wainwright. question Next line Emanuela

open. Your is line

Emanuela Branchetti

explore in happened for potential fact, guys so you while than-- my Good are other with higher question. do afternoon, me, data a possibility of to work ATYRXXXX And to pivotal XXXX, the before and different the for formulation thank formulation to any planning trial, the a and you for guys waiting taking

Sanjay Shukla

Hi Emanuela.

So, that's great question. a

patients patient from that. view company, IV could administered wants quickly, is administration. once think things lifecycle with perspective, of very from subcu perhaps want they month their planning, you small administration, a these certainly, I even something as that. point think lifecycle a advancing who But that like as be a we to at you then establish but look look easier proof-of-concept therapy great, a I our at in of a lot when than they consider of When companies

we're first, patients, could make think That's every you the that strategy. -- even I of see to proof-of-concept lifecycle absolutely some going at subcu question three perhaps with administration a from what think a things planning. look therapies in standpoint, I six here can they more formulation to that establish a as -- administered to attractive then we be therapy of advance your months. formulations lot makes But sense first

Emanuela Branchetti

China in certainly, entities -- we see Sure. you regards Thank move this? coming platform And have should throughputs of your and multiple INDs a to should -- And timelines? how for they start expect know, the clinical or Also, expectation can it's you can your I Would by developed with terms then on sense potential you give U.S. but this share us program? in fight of development thoughts forward Pangu, that. to from we have the assets? being you you

Sanjay Shukla

here thinking, an really this is start that you're it but I platform. the biology described, think talking. to we'd the early. the to goal to a to then really to be IND understand advance an to Yes, way leads candidate is like tend We is identify like that discovery able to discovery from area. our opportunity this definitely be We start and

just this I look think Mainland moment, with to a to an But that we'll how Hong strategy you. stronger do be there's more to ability have bit But We Kong With more getting right as would have on the because about little the emerge new like think, a milestone. it's situation, China. it the back it I we to we is I hesitate think just of put from -- think that. little say to candidate too first that's pay becoming to step the things working attention and to it you a to think have during pipeline I although, to. a interface is that be of at little a to this that's do different of discovery we'll that a gotten a little a regards provide on through bit with bit as to future, would those much is -- I we kind to platform. the with we here. Do regard actually connection in work thereby candidate discovery development, early a updates timeline specifically?

Emanuela Branchetti

in with looking in growth triple-negative When conjunction And, maybe the models, you. reported again, used AACR another Thank ATYRXXXX breast question. at the the cisplatin forward looking results and inhibit Sure. when to tumor bevacizumab. cancer seems

these you population? would forward talk this move the about the behind more do you should treatment development the of how So clinical you action drug with decide think in before positioned for mechanism the effects. But be breast better of to triple-negative cancer,

Sanjay Shukla

not clearly quite improve amazing room a lot where years TNBC. of in again, the bit still drug still what of have mechanistic utility, seeing in bit of to have therapy. And data made only how here, we chime aggressive we inhibition can of develops. help And think tumor a also Leslie might There's have can very a add and who also We but of become that efficacy. resistance cancer you're to that growth, strides And have and I'll couple I of patients but we resistant treating that are form a to understanding last Sure. a really be occurring. might existing is our quite learning exciting that

can Leslie specifically thoughts some that add also her more data. So of about

Leslie Nangle

Yes, absolutely.

strong we the types strong cancer, Dr. data amount -- made connection aggressive the have of they we different breast with specifically and a most we've solid because number amount of have our there. of of And where lab, generated in UMass of focus most So Mercurio’s a tumors. Arthur triple-negative

lot expression, think is lot with very And we're seeing. issues and a has very high coming resistance getting well. I a therapies. captures NRPX you're it of where of So is early this that type has Sanjay out to very current data that tumor And of that a aggressive

that me tumor see. so And is seeing organoids especially that we're we to interesting

patient to the changing So cell seeing these mechanism a this response XXXX. ENT, processes are and derived tumor are presence sensitizing stem the of development organoids where those of organoids, the that therapies. are organoids surrounding to understanding conventional we're in tumor see able of the bevacizumab we a or we're gene And indicating treatment, type directly or in chemotherapy being reversed

with will And that that do that and be so population something potential together that be a figure piece is helped could that mechanism we're particular. to in be -- out that really could starting that

Emanuela Branchetti

much. Got Thank very you it. it. Got

Operator

question open. Please Capital line the of Zegbeh Partners. Your from Jallah ROTH comes next from

Zegbeh Jallah

congrats Hi, really Leslie, guys. Thanks you. for for taking exciting questions, and my

of Just couple have a questions.

some to of the questions been follow-up just think asked. have that I

the make wanted have place? me, agreement first is one I with in that Pangu, is that you're the platform, for some full to retaining you of think that in to sure rights terms of or kind bi-specific just relationship

Sanjay Shukla

And Zegbeh. retaining the work that we rights are there. that's full a question, Certainly, Yes. great yes, for do we

explore think what of a think I So a opportunity we for us retaining that's to component is of key the bi-specific. value really outstanding

Zegbeh Jallah

else the but next really you. waiting someone one, still with for XXXX. then of Thank another in know I data, the on you good to participated sarcoidosis. for that concerns call the patients articulating follow-up about in again, like we're terms the pulmonary And was steroids alluded using really

I And going if so that's patients pivotal setup is study for of probably how out to the X figuring of was Phase less I just potentially up just study? kind steroids, wondering was if your who X, in same Kyorin wondering, terms that's this be set use

Sanjay Shukla

Yes.

its closely. interrogate accelerating -- validity that to think that at -- need that well is endpoint an I basically in look really may something to we are

looking or case, is, steroids working they with the the plus now, of don't think at meaningfulness some on clinical steroids. with go We we’re patients the but the want what off time thought causes heard to the call quite heard was Mary XX educating higher, them get FDA, FSR that over that they all. you you've endpoint, think bit always that on milligrams I new at I at are certainly their doses a in spending CEO, around

first I fact FSR. the sarcoidosis thus a at can by alternative our given think, as of particular, I line poised is momentum, the there's more that in said, approach. could But standard think the a something And and based therapy, I quickly, more and patients, our very first with therapy, So we far be transformative safety we just well this sense mechanism becoming corticosteroids steroids, profile. proof especially think therapy line -- on really have a we're demonstrated is looked spotlighted a better for we as of being more option great more in as here that endpoint I

Zegbeh Jallah

any Sanjay. just else with CSL mentioned, really be follow-up Lonza. efforts guys sounded NRPX I point left Thanks, cell of antibody the because the partnership was you your on on one discovery that efforts at just with is for got just what then exciting? data the biology. updates focusing to kind here, NK on I your comments with the on And IND? that some And adding the wonder then excited then done lastly, AACR of last with I wondering Behring, think

Sanjay Shukla

for progress what get neuropilin to expect -- regard the we to I like With to next program, inincredible we'd our steps cancer. to as in here said, in be

a of to continue different sides. neuropilin look models, we in tumor in we at different is as implicated tumor So vivo number models, know

have take can that on cancer for trial. think where will in focus that first we'll basically we other our best indication our to models. where few be us should a then So And best we allow effects our to

that for out patients will a attention before as very locked year. on with important everyone's working can this of the we're then of reason okay, throughout should for finishing remainder highlight the the focus best active its that think work is some preeminent, for here's of this was that into where the the see move there, get if us clinic. expect follow that why with actually of it will, the work to up. collaboration Lonza best because course We'll who what the I utility. this to really required you data, And complete So relationship translational which is we important is the you that to us actually And to CDMO toxicology another be some has year opportunity XXXX help to,

clinical the chain manufacturers. So think I we estimating really important right the actually clinic. go material with to Also about now, lot supply companies demand have ready a are can the into

with CDMO. with think those and engage So for us ahead actually with plan get companies about, to that, ability about, we not a talk struggling hear of they're something and ahead because it's their to lot I

of not findings findings this are getting to of of NK this we put out regard those the mature lot cell, in to abstract. receptive have And So top Lonza. going With a earlier thrilled slow interest down. out we really about to is of some year we notch want us like transparent have some and a we put form publication there be still that, that to candidates, some or with to

tracking well. that's So

process to thoughtful the think We receptor dot the cross thing validating on important be make that neuropilin-X the we I's to I we're be of going I receptor next But and target, very our there. like T's, be I the like all in targets few very, sure is well now to in is, there program did we as those them. a that they all able years think to change what highlight much from would aspect the ago.

cart what's think I the for there in program. that's that

Zegbeh Jallah

Thanks and on this. congrats Perfect. again

Operator

next Instruction] comes the Laidlaw. [Operator question Your of Jen from from line Yale

is Your open. line

Yale Jen

Good and taking question. the afternoon, thanks for

question about XXXX. the is first Just want -- to

by that, readout to you the question is a the potential is a study. Just looking robust, I need quarter little third endpoint on pivotal which accepted or forward functional to type of way plus you steroid-sparing bit My a questions, the going endpoint primary the to if could type advance into potentially endpoint gain the guys that of approval? assume more if conduct is be

Sanjay Shukla

the Yeah. for into with Thanks, will question. pivotal trial. this and FDA and our Certainly, a to move involve interaction plans Yale the aggressively propose

when some need we of wait. folks of lot you a disease today. trial lifecycle on about like And here. talk I of of running patients years to think a rare set don't have these a XX therapy Many time

put ones patients are learning don't to steroids. these Secondly, as and on get steroids. to we want we're be diagnosed that off know want more newly And and the desperately more

So it's easy.

And that at for the is this been I years in the involved I've a end time The this steroids done this as patient and there's look the primary toxicity the on of in is we you a patient the steroid-sparing have in ever regulators momentum program, FSR certainly reason really bringing seriously community, as to also second moving the question, can significant here. point. in tell with how there internally, more focused direction. that Andrea, is why the advisor, engaging highlighting

have us and discussion for regulators with well more say now a as should of really up this sets primary endpoint. thought to it think I action a be the

I minimal will with think primary of right regulators. is what for be worldwide discussions now, composite momentum reduction part So will be I say building those at steroid the a a But right of now, really a outcomes that to the endpoint endpoint.

it I we've been focusing think well on for endpoint us sets up --. really as

Yale Jen

question another Okay. you find successful? any. therapy, Great. we in involved comments you competitors program helpful. the seems competing find is of first-in-class in have if mentioned few And and Do be EMT cannot could guys that least, called that you any to either also be potentially That's very this terms -- at or so are process in space, the you XXXX, is a for a which very space

Sanjay Shukla

companies, sense successful afraid science makes replica talk about you cutting-edge as we literally around has we founding [ph], scientific came like, so in some mechanistically. to and tremendously bold to the it Paul can the we're Cubist of Paul's as places and of times mylamin a Yale, it were see entrepreneur, not been long out be So of we lab.

those remodulating out for significantly make year, can stemless of some leaps if some that. pointed could therapy, me are there. findings resistance. We mesenchymal we're We about our Leslie to that even So in this attack cells, type in and here as said potentially think two be that authors really cancer have and that excited we a backbone of

an area much very that think is that untapped. I we think it's do So

Our understandings that mechanistic on pointing pointing in is us direction. us biology

we're potentially interest more we even area to going think, where for it. this And get ACR, again, an in follow more the see lead that I last meeting in is So at here, you the meeting EMP. in and

teach some perhaps will can in this an it. where area companies years, what learned about we've about five other be So we

working certainly So interesting think stay Leslie I going that is that. really that that's for be hard to on. area an tuned

Yale Jen

the generally tumor last immune work oncology be approach. microenvironment, all be therapies. of whether consider was And great. sense related is by in understood targets? the bi-specific NRP I an in terms given they device But here I the be that Okay, will as checkpoint the make your maybe specific -- target it related -- the question a of know IO in not consideration? type will kind any would could one thanks. any immune that don't other of And of or necessarily

Sanjay Shukla

the to is to here. something makes the I'm co sense And But for colocation to and I sure. neuropilin-X. Leslie, receptors don't other that aggregate as No, like say next to we does want have going locate here to me, well

response, are to So asset we we cell. a could and an bridge a attack we that create right, improvement. could another a much But turbocharge this to that cancer specific receptor, agonies it's you that create by understand can if we have you mechanistically be another very essentially and immune quarterback absolutely will an say

And were what I to we're So I want why the working Leslie, here. in you direction, rationale. a basically really for think you everything build were it's may to say this that candidate anything grant you? is do do our exactly able think part scientific we the of add letters I pointed that, now -- because we awarded we

Leslie Nangle

Absolutely.

T walked on cells bit located in know, the you expression tumor through the to around we call microenvironment. this today we that it see little So we a these as think NRPX that are I alluded for

them. cells suppressor tumor myeloid-derived name cells only to and the tumor-associated not couple also but So of itself, a

And we interplaying how and what's a role definitely through those we on mesenchymal this of of earlier we're year cells with with for Keystone So that in tumor. that activity these understand the the cells and mode poster more investigation neuropilin-X a might to heavy walk the presented out with. of be where happening epithelial

think, work strategy investigating sense makes So there's work or can go not itself it's we're the on at specific that think advice whether tuned, a it. stay out approach really I that heavily or really whether I will mechanism bear And it as that with and at monoclonal to well.

should mechanism open as data where drive science us new -- and said, cutting Sanjay and we go. let to try we the we're So to be the edge in on really

open think very the And drug these to best way so to targets. we're I

so, tuned. And stay

Yale Jen

far. the a again, so congrats lot. And Thanks great. progress on Okay,

Operator

Sanjay And sir. over the there I to are call no like at back further phone this line over the questions time. would turn Shukla, to

Sanjay Shukla

but Thank you. biology questions we're Pangu interest advances or program, well. today, the making as our not and Great a in clinical neuropilin in large obviously bi-specific platform only

of for to up a looking I you area the of really today, our have forward speaking lot appreciate picked think new everyone calls. pipeline. opens from many and interest that up Really intriguing potential on you on questions to future

So well. thanks, everyone, be

Operator

Ladies and gentlemen, participating. thank concludes this for all call. today's conference We you

disconnect. You a may day. Have now great

aTyr Pharma (ATYR) 14 May 212021 Q1 Earnings call transcript